Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

forbes.com - Nithin Mummaneni - ​Your Pharma Contract Is Approved. But Is It A Competitive Deal?
​Your Pharma Contract Is Approved. But Is It A Competitive Deal?
Forbes –

Nithin Mummaneni is the founder and CEO of Infinity Loop. A 300-page pharmaceutical outsourcing agreement can clear legal, quality, regulatory and technical review without anyone asking whether the price is competitive. ​Each department…

bloomberg.com - Souhail Karam - Laprophan Raises $223 Million in Africa's Largest Pharma IPO
Laprophan Raises $223 Million in Africa's Largest Pharma IPO
Bloomberg –

Laprophan raised 2.22 billion dirhams ($223 million) in an initial public offering on the Casablanca stock exchange, the largest flotation by an African pharmaceutical company. The Moroccan firm sold 6.52 million existing and new shares at 341…

smh.com.au - Andrew Todd - ASX Runners of the Week: Black Rock, Mayne Pharma & Metal Hawk
ASX Runners of the Week: Black Rock, Mayne Pharma & Metal Hawk
The Sydney Morning Herald –

There's only one word to describe markets this week… Carnage. As of mid-market Friday, the ASX is in the midst of its seventh straight losing session, a plunge of more than six per cent that has now wiped out every cent of its 2026 gains. It…

seekingalpha.com - Equity Eagle - Avalyn Pharma: The Tolerability Budget Is The Real Battleground In Pulmonary Fibrosis
Avalyn Pharma: The Tolerability Budget Is The Real Battleground In Pulmonary Fibrosis
Seeking Alpha –

Avalyn Pharma offers lung-directed delivery of proven antifibrotics, potentially preserving tolerability as IPF and PPF regimens incorporate additional systemic agents. AP01 targets PPF label expansion, while AP02 and combination candidate AP03…

axios.com - Brock E.W. Turner - Scoop: Pharma marketing startup Doceree seeking $100M in growth capital
Scoop: Pharma marketing startup Doceree seeking $100M in growth capital
Axios –

Axios Pro Exclusive Content 28 mins ago…

iclg.com - Verity Jackson - Johnson Winter Slattery guides on acquisition of women's health specialist pharma company
Johnson Winter Slattery guides on acquisition of women's health specialist pharma company
ICLG –

The acquisition will boost the buyers' position within the women's health sector in Europe and globally. Australian law firm Johnson Winter Slattery has advised pharmaceutical manufacturer Gedeon Richter on its acquisition of Mayne Pharma Group via…

247wallst.com - Chris Lange - 3 Big Pharma Dividend Stocks Built for Retirement Income
3 Big Pharma Dividend Stocks Built for Retirement Income
24/7 Wall St –

A retirement portfolio needs income that holds up through patent cliffs, and the world's largest drugmakers have spent decades replacing old blockbusters with new ones while the dividend checks keep coming. Bristol Myers Squibb (NYSE:BMY | BMY…

marketbeat.com - Avalyn Pharma (NASDAQ:AVLN) Insider Sells 13,300 Shares of Stock
Avalyn Pharma (NASDAQ:AVLN) Insider Sells 13,300 Shares of Stock
MarketBeat –

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) insider Howard Lazarus sold 13,300 shares of the business's stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $27.90, for a total transaction of…

marketbeat.com - Spyglass Pharma (NASDAQ:SGP) Shares Gap Down - Here's Why
Spyglass Pharma (NASDAQ:SGP) Shares Gap Down - Here's Why
MarketBeat –

Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) shares gapped down prior to trading on Thursday. The stock had previously closed at $31.43, but opened at $29.73. Spyglass Pharma shares last traded at $28.47, with a volume of 5,982 shares…

statnews.com - Ed Silverman - Pharmalittle: We're reading about a Merck AI deal, China and the pharma supply chain, and more
Pharmalittle: We're reading about a Merck AI deal, China and the pharma supply chain, and more
STAT –

Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us. As for the official mascots, they have finished keeping…

marketbeat.com - Urogen Pharma (NASDAQ:URGN) Stock Price Up 6.8% - Still a Buy?
Urogen Pharma (NASDAQ:URGN) Stock Price Up 6.8% - Still a Buy?
MarketBeat –

Urogen Pharma (NASDAQ:URGN - Get Free Report)'s stock price rose 6.8% on Thursday. The company traded as high as $31.83 and last traded at $31.8150. 317,146 shares were traded during mid-day trading, a decline of 64% from the average daily volume…

marketbeat.com - Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up - Should You Buy?
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up - Should You Buy?
MarketBeat –

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report)'s share price gapped up prior to trading on Thursday. The stock had previously closed at $19.20, but opened at $20.48. Nuvectis Pharma shares last traded at $20.2750, with a volume of 7,363…

marketbeat.com - 365,074 Royalty Pharma PLC $RPRX Shares Sold by Aberdeen Group plc
365,074 Royalty Pharma PLC $RPRX Shares Sold by Aberdeen Group plc
MarketBeat –

Aberdeen Group plc trimmed its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 63.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 213,127 shares of the…

swissinfo.ch - swissinfo.ch - Zurich University Hospital performs brain surgery using a hologram
Zurich University Hospital performs brain surgery using a hologram
www.swissinfo.ch –

The precise placement of what is known as an external ventricular catheter in a patient's brain has, until now, been a major challenge, the Zurich University Hospital stated on Thursday. The thin tube must be inserted into a ventricle of the brain…

swissinfo.ch - swissinfo.ch - WEF role 'option' for Lagarde after leaving ECB
WEF role 'option' for Lagarde after leaving ECB
www.swissinfo.ch –

“It's one of the options,” she said at the New York Times DealBook Summit. “But for the moment, I'm the president of the European Central Bank, and will be so until Febuary 7. And I'm not going to entertain any sort of…

Receive a Daily briefing on Pharma Industry News

Get Started